FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979666586> ?p ?o ?g. }

• W2979666586 abstract "Abstract Abstract 3113 Poster Board III-50 Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. Mutations of JAK2V617F were described in the majority of MPN patients but only about half of those undergoing blastic transformation continue to harbor that mutation. We describe a cohort of 23 patients from Roswell Park Cancer Institute (RPCI) and discuss 90 additional cases from the English literature for whom biologic features were described. We also screened our cases for JAK2V617F, JAK2T875N and MPL515L/K. We initially compared our 23 patients to the 90 cases from the literature. Our population had significantly less patients with prior history of polycythemia vera (22% vs. 53%; P<0.0001), shorter time from MPN diagnosis to blastic transformation (<5 years to transformation in 68% vs. 40%; p=0.0296), <3 prior therapies (100% vs. 16%; p<0.0001), more frequent use of hydroxyurea (63% vs. 27%; p=0.0056), less frequent use of alkylating agents (5% vs. 54%; p<0.0001) and more frequent use of erythropoietin (11% vs. 0%; p=0.0332). Detection of normal karyotype at the time of blastic transformation was more common in the RPCI population (35% vs. 7%; p=0.0033). The two populations did not differ in regards to age at diagnosis of MPN or blastic transformation, gender, prior use of interferon or karyotype aberrations. Interestingly, the overall survival of the two cohorts from the time of blastic transformation was similar [3 vs. 5 months; 95% confidence interval (CI) 2 to 5 vs. 3 to 9; p=0.1639]. We therefore looked at the outcome of the entire cohort (n=113). Patients with prior history of essential thrombocythemia survived longer (8.6 months; 95% CI 4.3, 24) than patients with prior history of myelofibrosis (4.5 months; 95% CI 2, 11) or polycythemia vera (3 months; 95% CI 2, 5) (p=0.0224). Further, patients with <3 prior therapies had significantly longer survival (8 vs. 3 months; 95% CI 4 to 11 vs. 2 to 5; p=0.0212). Finally, patients with complex karyotype had significantly shorter survival (3 vs. 5 months; 95% CI 2 to 5 vs. 3 to 10); p=0.0272). No difference in survival was detected based on time from MPN diagnosis to blastic transformation, age, prior hydroxyurea treatment, prior alkylating agents, erythropoietin, or interferon, or presence of non-complex karyotype aberrations. We then evaluated the treatment response among the PRCI patients (n=23). A total of 20/23 patients underwent induction treatment with cytarabine and an anthracycline containing regimens; 12 achieved remission and eight did not. The overall survival of those achieving remission was significantly longer than those who did not [13 vs. 3 months; 95% CI 8 to 25 vs. 2 to 4); p<0.0001]. Three patients underwent an allogeneic transplantation and their survival was significantly longer that those who did not [11 vs. 4 months; 95% CI 8 to 57 vs. 3 to 5; p=0.0119]. Samples were available for eight of the patients at disease transformation; JAK2V617F was detected in two and none had T875N or MPL515K/L. In summary, patients with less than three prior therapies and lack of complex karyotype have longer survival following blastic transformation. Finally, allogeneic transplantation represents the only chance for long term survival in these patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2979666586 created "2019-10-18" @default.
• W2979666586 creator A5008341315 @default.
• W2979666586 creator A5016601438 @default.
• W2979666586 creator A5038660651 @default.
• W2979666586 creator A5039028985 @default.
• W2979666586 creator A5040198845 @default.
• W2979666586 creator A5043287179 @default.
• W2979666586 creator A5046140518 @default.
• W2979666586 creator A5053179535 @default.
• W2979666586 creator A5075486570 @default.
• W2979666586 creator A5077133890 @default.
• W2979666586 date "2009-11-20" @default.
• W2979666586 modified "2023-09-26" @default.
• W2979666586 title "Myeloid Blastic Transformation of Myeloproliferative Neoplasms – A Review of 113 Cases." @default.
• W2979666586 doi "https://doi.org/10.1182/blood.v114.22.3113.3113" @default.
• W2979666586 hasPublicationYear "2009" @default.
• W2979666586 type Work @default.
• W2979666586 sameAs 2979666586 @default.
• W2979666586 citedByCount "0" @default.
• W2979666586 crossrefType "journal-article" @default.
• W2979666586 hasAuthorship W2979666586A5008341315 @default.
• W2979666586 hasAuthorship W2979666586A5016601438 @default.
• W2979666586 hasAuthorship W2979666586A5038660651 @default.
• W2979666586 hasAuthorship W2979666586A5039028985 @default.
• W2979666586 hasAuthorship W2979666586A5040198845 @default.
• W2979666586 hasAuthorship W2979666586A5043287179 @default.
• W2979666586 hasAuthorship W2979666586A5046140518 @default.
• W2979666586 hasAuthorship W2979666586A5053179535 @default.
• W2979666586 hasAuthorship W2979666586A5075486570 @default.
• W2979666586 hasAuthorship W2979666586A5077133890 @default.
• W2979666586 hasConcept C104317684 @default.
• W2979666586 hasConcept C121608353 @default.
• W2979666586 hasConcept C126322002 @default.
• W2979666586 hasConcept C143998085 @default.
• W2979666586 hasConcept C204241405 @default.
• W2979666586 hasConcept C2778837598 @default.
• W2979666586 hasConcept C2779282312 @default.
• W2979666586 hasConcept C2780007613 @default.
• W2979666586 hasConcept C2780076729 @default.
• W2979666586 hasConcept C2908647359 @default.
• W2979666586 hasConcept C2908731994 @default.
• W2979666586 hasConcept C502942594 @default.
• W2979666586 hasConcept C54355233 @default.
• W2979666586 hasConcept C71924100 @default.
• W2979666586 hasConcept C72563966 @default.
• W2979666586 hasConcept C86803240 @default.
• W2979666586 hasConcept C99454951 @default.
• W2979666586 hasConceptScore W2979666586C104317684 @default.
• W2979666586 hasConceptScore W2979666586C121608353 @default.
• W2979666586 hasConceptScore W2979666586C126322002 @default.
• W2979666586 hasConceptScore W2979666586C143998085 @default.
• W2979666586 hasConceptScore W2979666586C204241405 @default.
• W2979666586 hasConceptScore W2979666586C2778837598 @default.
• W2979666586 hasConceptScore W2979666586C2779282312 @default.
• W2979666586 hasConceptScore W2979666586C2780007613 @default.
• W2979666586 hasConceptScore W2979666586C2780076729 @default.
• W2979666586 hasConceptScore W2979666586C2908647359 @default.
• W2979666586 hasConceptScore W2979666586C2908731994 @default.
• W2979666586 hasConceptScore W2979666586C502942594 @default.
• W2979666586 hasConceptScore W2979666586C54355233 @default.
• W2979666586 hasConceptScore W2979666586C71924100 @default.
• W2979666586 hasConceptScore W2979666586C72563966 @default.
• W2979666586 hasConceptScore W2979666586C86803240 @default.
• W2979666586 hasConceptScore W2979666586C99454951 @default.
• W2979666586 hasLocation W29796665861 @default.
• W2979666586 hasOpenAccess W2979666586 @default.
• W2979666586 hasPrimaryLocation W29796665861 @default.
• W2979666586 hasRelatedWork W1491698768 @default.
• W2979666586 hasRelatedWork W1990520184 @default.
• W2979666586 hasRelatedWork W2008161572 @default.
• W2979666586 hasRelatedWork W2018253607 @default.
• W2979666586 hasRelatedWork W2065160838 @default.
• W2979666586 hasRelatedWork W2070839556 @default.
• W2979666586 hasRelatedWork W2409414984 @default.
• W2979666586 hasRelatedWork W2555890294 @default.
• W2979666586 hasRelatedWork W2571194692 @default.
• W2979666586 hasRelatedWork W2732761160 @default.
• W2979666586 hasRelatedWork W2755335280 @default.
• W2979666586 hasRelatedWork W2775381743 @default.
• W2979666586 hasRelatedWork W2791166792 @default.
• W2979666586 hasRelatedWork W2800409441 @default.
• W2979666586 hasRelatedWork W2892133238 @default.
• W2979666586 hasRelatedWork W2900126078 @default.
• W2979666586 hasRelatedWork W2994224690 @default.
• W2979666586 hasRelatedWork W3138849924 @default.
• W2979666586 hasRelatedWork W3162870554 @default.
• W2979666586 hasRelatedWork W9782988 @default.
• W2979666586 isParatext "false" @default.
• W2979666586 isRetracted "false" @default.
• W2979666586 magId "2979666586" @default.
• W2979666586 workType "article" @default.